“My Botox used to work. Why does it seem weaker now?”
A weaker result, an effect that wears off sooner, or little response after repeated appointments can raise the question of Botox resistance. One disappointing treatment, however, does not establish the cause.
I’m Dr. Youro, a physician practicing aesthetic medicine in South Korea. Here is how to approach a change in your results—and what to check before booking another injection.
The key point: antibody-related resistance is uncommon in cosmetic treatment. Start with the treatment record: product, dose, injection sites, dates and actual muscle response.
“Botox” is often used casually for anti-wrinkle injections or neuromodulators. BOTOX is also a specific brand of botulinum toxin type A. Products and their potency units are not interchangeable.
1. Three changes that deserve a closer look
| What changes? | What you might notice |
|---|---|
| A weaker effect | Frowning or raising your eyebrows produces more movement than after comparable previous treatments. |
| A shorter-lasting effect | The benefit repeatedly fades earlier than it used to under similar treatment conditions. |
| Repeatedly little or no response | A treatment that previously worked produces minimal benefit over successive appointments. |
Doctors use secondary nonresponse to describe loss of benefit after an earlier response. Antibodies are one possible cause; dose, muscle selection and injection technique also need review. [1]
Gradual wearing off is expected. For example, the US BOTOX Cosmetic label describes an approximately three- to four-month effect for frown lines. That is a product- and treatment-specific guide, not a promise for every area or person. [3]
2. What causes antibody-related Botox resistance?
The active neurotoxin is a protein. In some people, the immune system produces neutralizing antibodies that interfere with its activity. These antibodies target the active toxin—not simply the extra proteins present in some formulations. [1] [2]
Those extra complexing proteins are separate from the active toxin. Removing them may be relevant when discussing immunogenicity, but it does not make a product resistance-proof: the active toxin protein remains. [1]
3. How common is it in cosmetic treatment?
A 2023 analysis pooled 33 onabotulinumtoxinA trials. Among 5,876 people with evaluable antibody data across cosmetic and medical uses, 27 (0.5%) developed neutralizing antibodies. Five lost an earlier treatment response; all five were in medical-treatment groups. [2]
| Cosmetic group in that analysis | Antibodies detected after treatment |
|---|---|
| Frown lines | 3 of 810 people (0.4%) |
| Crow’s feet | 0 of 915 people (0%) |
These cosmetic groups included 1,725 people followed for up to five treatment cycles. None remained antibody-positive at study exit. A positive antibody result and actual loss of treatment benefit are different findings. [2]
The analysis was supported by AbbVie and studied one product. It cannot establish a lifetime risk for every brand, dose or cosmetic use. Rare antibody-associated failures have also been documented in aesthetic case reports. [2] [5]
4. Botox seems weaker: what should you check first?
- When was it assessed? An immediate post-treatment photograph cannot show the final effect. Reduced muscle movement and a change in masseter size are different outcomes; agree on a review time for the area treated.
- Was the treatment comparable? Check the exact product, units by area and injection sites. A different brand or a lower-dose plan may produce a different result.
- What change were you expecting? A line visible at rest, jawbone shape, facial fat or loose skin will not necessarily improve just because a muscle relaxes.
- Is there objective loss of response? Compare photographs under similar lighting, both at rest and with the same facial movement, alongside the treatment record.
For BOTOX Cosmetic, correct dosing, product preparation and knowledge of the treated anatomy are fundamental to the result. Ask your clinician to review these factors before attributing a weak response to antibodies. [3]
5. Treatment intervals and total dose
Leave enough time between treatments
For routine cosmetic retreatment, three months or longer is a useful starting point for discussion. The US BOTOX Cosmetic label states that treatment more often than every three months has not been clinically evaluated for safety and effectiveness. [3]
This is not a requirement to return exactly every three months. If the benefit remains, you may be able to wait longer. Use the lowest effective dose and avoid unnecessary repeated booster or “top-up” injections. The interval must suit the product, treatment area and remaining effect. [4] [5]
Does staying below 400 units prevent resistance?
No. 400 units is an adult cumulative dosing limit over three months in the US BOTOX prescribing information. It is not an antibody-resistance threshold or a cosmetic treatment target. Staying below it does not guarantee freedom from resistance or other adverse effects. [4] [5]
That number cannot be transferred to Dysport or other toxin brands. Their units are product-specific, and the appropriate dose for an individual area may be much lower. [3] [4]
These are US label references. Your clinician should follow the relevant product information and local requirements where treatment takes place, including in the UK or South Korea.
6. Will switching to Xeomin make Botox work again?
Not necessarily. Xeomin (incobotulinumtoxinA) has complexing proteins removed, but it still contains an active type A neurotoxin. If antibodies against that toxin are responsible, changing to another type A brand may not restore a satisfactory response. [1] [5]
A published aesthetic case series documented limited benefit after switching between type A products, including Xeomin, in a patient who tested positive for antibodies. This does not predict every patient’s outcome, but it shows why a brand switch is not a guaranteed fix. [5]
For the differences between products offered in Korea, see Botox Brands in Korea: Coretox, Xeomin and BOTOX Compared.
7. How is suspected resistance assessed?
A clinician first reviews your treatment history and muscle response. If needed, a controlled test in a small brow or forehead muscle area can show whether the toxin still weakens that muscle. This is a clinical response test, not a direct blood test for neutralizing antibodies. [1]
Specialized antibody tests have limitations and must be interpreted alongside the clinical findings. A selfie, online checklist or one poor result cannot confirm antibody-related resistance. [1]
Quick answers
Can Botox stop working after just one or two treatments?
The number of appointments alone cannot diagnose resistance. Check assessment timing, dose and targeting first. Repeated loss of a previously reliable effect deserves a clinical review. [1]
Will a six-month or one-year break reset it?
There is no guaranteed reset period. Antibody levels may fall with time, but whether and when a useful response returns varies. Discuss a plan rather than repeatedly testing new brands on your own. [1] [5]
Should I get a top-up before flying home from Korea?
Arrange a review, but let the clinical findings determine whether another injection is appropriate. A departure date is not a reason to bring treatment forward. Share any injections received at another clinic, including medical treatments, and ask how follow-up will work after you return home.
What should I bring to the consultation?
- The exact product name, treatment dates and units used in each area.
- Details of all treated areas and any early top-ups or injections at other clinics.
- When the effect first appeared, when it was strongest and when it faded.
- Comparable photographs and a clear description of what changed.
If the effect has repeatedly weakened, the next useful step is a review of your record and muscle response. This gives you and your clinician a better basis for deciding whether the plan, product or further assessment should change.
Difficulty swallowing, speaking or breathing after an injection requires urgent medical attention. [3]
Related reading
- How Botox Works: Muscle, Skin and Salivary Gland Treatments
- Botox in Korea: Timing, Brands & Aftercare
References
1. Bellows S, Jankovic J. Immunogenicity Associated with Botulinum Toxin Treatment. Toxins. 2019;11(9):491. Read source.
2. Jankovic J, Carruthers J, Naumann M, et al. Neutralizing Antibody Formation with OnabotulinumtoxinA (BOTOX) Treatment from Global Registration Studies across Multiple Indications: A Meta-Analysis. Toxins. 2023;15(5):342. Manufacturer-supported analysis. Read source.
3. AbbVie. BOTOX Cosmetic US prescribing information. Sections 2.1–2.4, 5 and 12.6. Read source.
4. AbbVie. BOTOX US prescribing information. General dosing instructions and immunogenicity section. Read source.
5. Torres S, Hamilton M, Sanches E, et al. Neutralizing antibodies to botulinum neurotoxin type A in aesthetic medicine: five case reports. Clinical, Cosmetic and Investigational Dermatology. 2014;7:11–17. Published online December 2013. Read source.
By Youro Kang, MD, a physician practicing aesthetic medicine in South Korea. Adapted for English-speaking readers from my original Korean article on Botox resistance. Educational information; an individual treatment plan requires a clinical assessment.
Your own, Dr. Youro
Leave a Reply